NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
According to recent industrial report, only several products from worldwide NMN manufacturers came close to meeting label claim and contain not enough NMN. Almost products performed better, having at least 88% of the label claim up to small overages. A lone 250 mg product was identified as BRL. In sum, ChromaDex said that 64% of the products tested contained less than 1% of the stated amount of the active ingredient. which should give consumers pause. While this is a limited snapshot of the vast NMN finished product landscape. it does provide a glimpse into the high variability of product quality that is available. The majority of the products may purchase online contain such a small amount of NMN that there would be no clinical benefits achieved from the dose. Another concern with these adulterated products is that the actual contents are not known and could pose a risk to the user the company said in a statement.
NMN powder in general is typically produced via chemical or enzymatic synthesis, or fermentation biosynthesis. There are pros and cons to all three methods.
Chemical synthesis is expensive and labor intensive, and all raw ingredients used are categorized as “unnatural,” i.e., not from biological systems. There are, however, some advantages from the manufacturer’s perspective. The yield is well suited to mass NMN powder production, and all of those unnatural raw ingredients can be carefully controlled. But there are a number of drawbacks as well. Some of the solvents used in the manufacturing process are seriously bad from an environmental standpoint, and impurities and by-products can be challenging to remove from the finished product – that’s seriously bad for the consumer.
Enzymatic production of NMN powder, on the other hand, is considered a “green preparation method.” Like the chemical route, it’s pricey, but it offers a higher yield and impressively high purity. The finished NMN ticks all the boxes – stable, easily absorbed, lightweight, low density, and a low molecular structure.
Fermentation has also been explored as a method of producing NMN, but yield, though high quality, is pretty abysmal, so many supplement companies quite sensibly look to other, more efficacious processes.
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability of production of NMN powder
3、Industrial leading technology: 15 domestic and international NMN patents
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
5、Multiple in vivo studies show that Bontac NMN powder is safe and effective
6、Provide one-stop product solution customization service
7、NMN raw material supplier of famous David Sinclair team of Harvard University.
1.Raw material production process
Bioenzyme catalysis is a popular production method in the industry. It has a high threshold and several key catalytic enzymes are expensive, accounting for about 80% of the overall production process cost, but it is also the safest and most efficient production method. In the production of NMN by bioenzyme catalysis, the use of food-grade raw materials is an important part of the process to ensure product safety and to ensure that standards are followed.
2.High standard of production conditions
Production conditions refer to the standard of labor consumption required to complete the qualified products of the unit under certain production organization and production technology conditions. There are certifications issued by regulatory authorities, such as cGMP in the United States, TGA in Australia, GMP in Japan, etc.
3.High standard of product testing.
Product testing requires reliable test methods and reagents that are used throughout the production process. They are not only inspection standards for the final product, but also for the intermediate stages of control, including testing of active ingredients, testing of heavy metals such as lead, arsenic and mercury, and testing of pathogenic bacteria, microorganisms and processing by-products.
For NMN products, the commonly used method for active ingredient content testing is high performance liquid chromatography (HPLC), which is efficient, accurate and precise. For different manufacturers, the standards for testing reagents are different. Strict manufacturers will purchase high purity, analytically pure reagents from third party standards companies as controls.
4.Safety assessment
For relatively new raw materials such as NMN, it is not enough for consumers to judge the safety of the product on the side of the merchant alone. At this point, the third-party authoritative assessment report is particularly important.
Currently, there are two generic safety assessment reports, one is a toxicological assessment report and the other is a safety assessment report. In China, toxicological assessment reports usually account for the majority. However, there are still few NMN companies that can issue such reports
5.Storage and Packaging
NMNs are usually stored in sealed containers for up to 12 months. If it can be stored for 24 months with insignificant changes in purity, the stability of NMN is very reliable. Currently, the more common packaging materials are pet or hope, which are pharmaceutical packaging materials. They are non-toxic, odorless, lightweight, portable and effectively isolate air and moisture.
The safety of NMN powder cannot be assessed since required clinical and toxicological studies have not been completed yet to establish the recommended safe levels for long term administration. Nevertheless, their safety and efficacy are uncertain and unreliable since most of them have not been backed up by rigorous scientific preclinical and clinical testing. This issue has been arisen as manufacturers are hesitant to pay for research and clinical trials due to potential lower profit margin, and there is no authorizing agency to regulate NMN products because it is often sold as functional food product rather than heavily regulated therapeutic drug. Therefore, more strict approval process has been demanded by consumer advocacy groups requesting regulatory agencies to set standard and restrictions for marketing anti-aging health products, considering safety, health and wellbeing of consumers. NMN should not be considered as a panacea for the elderly, because boosting NAD levels when not required may yield some detrimental effects. Therefore, the dose and frequency of NMN supplementation should be carefully prescribed depending on the type of age-related deficiency and all other confronting health conditions of the people. Other NAD precursors have been studied to discover the efficacy for diverse age-related deficiencies and they are used for particular deficiencies, only after they are proven for effectiveness and safe to use. Therefore, the same principle should be applied to NMN as well
First, inspect the factory. After some screening, NMN companied that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMN powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMN powder produced by Bontac reach the purity of 99.9%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
1. Introduction At present, vaccine is the preferred option for the prevention of foot-and-mouth disease (FMD), for which the adjuvant is essential due to its strong role in boosting immune response associated with vaccine antigens. Herein, Rh2 liposomes (Rh2-L) are prepared by ethano injection methods, then loaded into a double emulsion adjuvant and emulsified into a Water-in-Oil-in-Water (W/O/W) emulsion, together with FMDV antigen, for the prevention of FMD. 2. About FMD FMD, also known as aphthous fever, is a viral and fulminating infectious disease in which the foot-and-mouth disease virus (FMDV) violates hoofed livestock such as cattle, pigs and sheep. Since FMD is a zoonotic disease with high incidence and fast transmission speed, FMD vaccination is significant for those with long-term contact with livestock or low immunity such as the herders, veterinarians and children. 3.The significance of transform Rh2 into Rh2-L By transformation of Rh2 into Rh2-L, on the one hand, the poor solubility and hemolysis of Rh2 can be mitigated to a large extent. On the other hand, Rh2-L functions as a liposome. Noteworthily, liposome itself has been revealed to be an adjuvant in vaccine design to improve immune response by interacting with antigen-presenting cells (APCs), increasing the representation of immune stimulants to APCs, and stimulating innate immunity. 4. The immune-enhancing effect of Rh2-L on FMD vaccine Rh2-L has a immune-enhancing effect, as evidenced by an increase in humoral and cellular immune responses. In the FMDV model, the group of the FMD vaccine prepared with double emulsion adjuvants containing Rh2-L presents a more desirable protective effect relative to other groups. This group has a higher neutralizing antibody titer, stronger lymphocyte proliferation responses, and higher levels of cellular and humoral immune cytokine production, including IFN-γ and IL-4. 5. Conclusion Rh2-L can further boost the immune effect of the double emulsion adjuvant against foot-and-mouth disease, which may be a promising and powerful platform for subunit vaccine adjuvant. 6. Reference Saiya Miao, Qiufang Jing, Xuanyu Wang, et al. “Immuno-Enhancing Effect of Ginsenoside Rh2 Liposomes on Foot-and-Mouth Disease Vaccine”. Molecular Pharmaceutics. 2024 21 (1), 183-193. DOI: 10.1021/acs.molpharmaceut.3c00733 BONTAC advantages BONTAC is ·the first enterprise in China to provide mass production of ginsenosides (Rh2) by enzymatic synthesis. BONTAC has unique Bonzyme enzymatic synthesis technology. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC has more than 160 invention patents, with strict third-party self-inspection. Both the high-quality product and excellent service can be better ensured here. BONTAC has 12 years of industry experience, which is worthy of your trust. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Introduction Cardiovascular diseases (CVD) poses huge economic burden and great threat to the life of patients, even surpassing Alzheimer's disease and diabetes. 17.9 million people in the world die from CVD, with indirect treatment costs of $237 billion per year, which are projected to increase to $368 billion by 2035. It has been reported that the deficiency or imbalance of oxidized nicotinamide adenine dinucleotide phosphate (NADP+)/reduced nicotinamide adenine dinucleotide phosphate (NADPH) redox couple has been linked to a variety of pathological conditions including CVD. NADP(H) redox couple as cofactor/electron carrier in cardiommyocytes NADPH is an essential cofactor of glutathione reductase (GR) and thioredoxin reductase (TRs) in cardiommyocytes, with a crucial role in maintaining cellular redox homeostasis and energy metabolism. GR catalyzes the recycling of Glutathion (GSH) from oxidized glutathione (GSSG), and TRs reduces oxidized Trx-S2 into Trx-(SH)2. Simultaneously, both enzymes require NADPH as an electron donor and oxidize it to NADP+. Once O2•− is formed, for example, from NOXs in the cytosol and from mitochondrial electron transport chain (ETC), cytosolic CuZnSOD and mitochondrial MnSOD will reduce it to H2O2. GSH can be used by glutathione peroxidase (GPx) to reduce H2O2 further to water. Trx-(SH)2 provides reducing equivalents for Prx in the removal of H2O2. The connection of NADP(H) with cardiovascular pathologies NADP(H) plays a dual role in cardiovascular pathologies. On the one hand, the reduced NADPH can result in significant antioxidant deficiencies and intracellular accumulation of free radicals, which triggers lipid peroxidation, inflammation, and vascular dysfunction, ultimately exacerbating the course of atherosclerosisoxidase. On the other hand, high NADPH level can give rise to myocardial injury by inducing reductive stress and enhancing reactive oxygen species (ROS) production. Conclusion Changes in cellular NADP(H) content affect the intermediary metabolism of cardiac function, especially in diseased myocardium. Maintaining the balance between NADP+ and NADPH in cardiommyocytes is critically important for the treatment of CVD. Either deficiency or excess NADP(H) levels can lead to imbalances in cellular redox state and metabolic homeostasis, resulting in energy stress, redox stress, and ultimately disease state. NADP(H) has an important therapeutic value in CVD. Reference Sun Y, Wu D, Hu Q. NADP+/NADPH in Metabolism and its Relation to Cardiovascular Pathologies. Curr Med Chem. Published online February 16, 2024. doi:10.2174/0109298673275187231121054541 BONTAC NADP(H) BONTAC has dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NADP(H). Bonzyme whole-enzymatic method is adopted, which is environmental-friendly, with no harmful solvent residues. The purity of NADP and NADPH can reach up to 95% and 98%, respectively, which is benefited from the exclusive Bonpure seven-step purification technology. BONTAC has self-owned factories and has obtained a number of international certifications, where high quality and stable supply of products can be ensured. BONTAC has four domestic and foreign NADPH patents, leading the industry. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Introduction Natural products, including single components or extracts of herbal medicines, have the features of good efficacy and low toxicity when used in tumor treatment. They have unique advantages in treating diseases compared with chemotherapeutic drugs due to their multi-component and multi-target effects. Strikingly, ginsenoside Rg3-loaded PLGA nanoparticles (Rg3-PLGA) coated with the membrane of tumor cell-derived microvesicles (Rg3-PLGA@TMVs), which is a nanoformulation of the natural product ginsenoside Rg3, have a significant role in the treatment of breast cancer when combined with the chemotherapeutic drug doxorubicin (DOX). Pharmacological roles of ginseng Rg3 in traditional Chinese medicine Ginseng Rg3, a tetracyclic triterpenoid saponin, is one of the main active component of ginseng. Ginseng has been regarded as one of the most valuable medicinal plants in Chinese traditional medicine for thousands of years, which is known as "the king of all tonic”. This perennial herb possesses the multiple pharmaceutical functions such as tonifying the vital energy, restoring the pulse and stabilizing the loss of vitality, invigorating spleen and benefiting lung, generating saliva or body fluid to quench thirst, as well as tranquilizing the mind and promoting the intelligence. The construction of Rg3-PLGA@TMVs Ginsenoside Rg3 is first encapsulated into PLGA nanoparticles using the nanoprecipitation method, followed by the extrusion-based coating of the TMV membrane onto Rg3-PLGA. This strategy combines the therapeutic properties of Rg3 with the precise delivery and sustained release capabilities of PLGA nanoparticles, further enhanced by the homologous targeting properties of TMVs. Anti-tumor effect and bio-safety of Rg3-PLGA@TMVs in 4T1 breast cancer Rg3-PLGA@TMVs induce robust anti-tumor immunity, recover the body weight loss caused by DOX in 4T1 breast cancer and overtly improve the anti-tumor effect of DOX, showing good stability and drug loading capability. These anti-tumor effects are chiefly realized by reducing phagocytic activity and acid phosphatase (ACP) levels, promoting the maturation of bone marrow-derived dendritic cells in vitro, and elevating the population of cytotoxic T lymphocytes (CD3+CD8+) and helper T cells (CD3+CD4+) in vivo. Importantly, this nanoformulation has minimal side effects and favorable biocompatibility, which can relieve the organ toxicity caused by DOX, especially the cardiac side effects. The administration of DOX and Rg3-PLGA@TMVs does not result in statistically significant changes in white blood cell (WBC) count and renal functional indicators, such as CREA and urea, nor in hepatic functional indicators, including AST and ALT. Conclusion Rg3-PLGA@TMVs achieve the co-delivery of antigens and adjuvants, which not only potentiate the anti-tumor effects, but also significantly alleviate the systemic toxicity caused by chemotherapeutic drugs, improving the overall health status of patients undergoing chemotherapy. Reference [1] Liu XR, Zhang KF, Li X, et al. Research progress on antitumor nanoscale drug delivery system of ginsenoside Rg3 [J]. Chin Trad Herb Drugs. 2023,54(22):7577-7587. DOI: 10.7501/j.issn.0253-2670.2023.22.034 [2]Zhang S, Zheng B, Wei Y, et al. Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviate toxicity [J]. Biomater Sci. Published online April 10, 2024. DOI:10.1039/d4bm00159a BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.